Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.

Abstract	Enteropathy-associated T cell lymphoma (EATL) is a rare entity associated with coeliac disease, with a poor prognosis due to perforation and gastro-intestinal bleeding during treatment, and a high relapse risk. Six patients were treated with two cycles of IVE (ifosphamide, etoposide, epirubicin), followed by two cycles of high-dose methotrexate (3 g/m(2)) with folinic acid rescue and a BEAM (carmustine, etoposide, cytarabine, melphalan) autograft. Enteral feeding was given throughout treatment. Four patients remain alive in complete remission at 1.83-4.32 years; two have relapsed. Given the historically poor outcome in these patients, this regimen appears very promising in the treatment of EATL.
Authors	Mark J Bishton, Andrew P Haynes
Journal	British journal of haematology (Br J Haematol) Vol. 136 Issue 1 Pg. 111-3 (Jan 2007) ISSN: 0007-1048 [Print] England
PMID	17116129 (Publication Type: Clinical Trial, Journal Article)
Chemical References	Immunosuppressive Agents Cytarabine Granulocyte Colony-Stimulating Factor Epirubicin Etoposide Podophyllotoxin Melphalan Carmustine Ifosfamide Methotrexate
Topics	Adult Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use) Carmustine (administration & dosage) Celiac Disease (complications, immunology, therapy) Combined Modality Therapy Cytarabine (administration & dosage) Enteral Nutrition Epirubicin (administration & dosage) Etoposide (administration & dosage) Female Granulocyte Colony-Stimulating Factor (therapeutic use) Humans Ifosfamide (administration & dosage) Immunosuppressive Agents (therapeutic use) Lymphoma, T-Cell, Peripheral (complications, therapy) Male Melphalan (administration & dosage) Methotrexate (therapeutic use) Middle Aged Peripheral Blood Stem Cell Transplantation Podophyllotoxin (administration & dosage) Transplantation Conditioning Transplantation, Autologous Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!